| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5399578 (Pediatric) | NOVARTIS | Acyl compounds |
Sep, 2012
(11 years ago) | |
| US6294197 | NOVARTIS | Solid oral dosage forms of valsartan |
Jun, 2017
(6 years ago) | |
|
US6294197 (Pediatric) | NOVARTIS | Solid oral dosage forms of valsartan |
Dec, 2017
(6 years ago) | |
| US6395728 | NOVARTIS | Method of treatment and pharmaceutical composition |
Jul, 2019
(4 years ago) | |
Exforge is owned by Novartis.
Exforge contains Amlodipine Besylate; Valsartan.
Exforge has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Exforge are:
- US5399578*PED
- US6294197
- US6294197*PED
- US6395728
Exforge was authorised for market use on 20 June, 2007.
Exforge is available in tablet;oral dosage forms.
Exforge can be used as treatment of hypertension.
The generics of Exforge are possible to be released after 08 July, 2019.
Drugs and Companies using AMLODIPINE BESYLATE; VALSARTAN ingredient
Market Authorisation Date: 20 June, 2007
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
How can I launch a generic of EXFORGE before it's drug patent expiration?
More Information on Dosage
EXFORGE family patents
